GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Price-to-Owner-Earnings

Ryvu Therapeutics (WAR:RVU) Price-to-Owner-Earnings : (As of May. 20, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics Price-to-Owner-Earnings?

As of today (2025-05-20), Ryvu Therapeutics's share price is zł33.00. Ryvu Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Ryvu Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Ryvu Therapeutics was 338.14. The lowest was 1.72. And the median was 3.65.


WAR:RVU's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 29.17
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-20), Ryvu Therapeutics's share price is zł33.00. Ryvu Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was zł-4.80. Therefore, Ryvu Therapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-20), Ryvu Therapeutics's share price is zł33.00. Ryvu Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was zł-5.04. Therefore, Ryvu Therapeutics's PE Ratio without NRI for today is At Loss.

During the past 13 years, Ryvu Therapeutics's highest PE Ratio without NRI was 432.75. The lowest was 0.00. And the median was 1.20.


Ryvu Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Ryvu Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics Price-to-Owner-Earnings Chart

Ryvu Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ryvu Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ryvu Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Ryvu Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Price-to-Owner-Earnings falls into.


;
;

Ryvu Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ryvu Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=33.00/-5.64
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ryvu Therapeutics  (WAR:RVU) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Ryvu Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Ryvu Therapeutics Business Description

Traded in Other Exchanges
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines